688578 艾力斯
已收盘 03-05 15:00:01
资讯
新帖
简况
3月4日艾力斯涨11.17%,银华中证创新药产业ETF基金重仓该股
证券之星 · 03-04 16:22
3月4日艾力斯涨11.17%,银华中证创新药产业ETF基金重仓该股
艾力斯:预计2026年1-3月营业收入15.5亿元
证券之星 · 03-03 18:00
艾力斯:预计2026年1-3月营业收入15.5亿元
艾力斯(688578.SH)发预增,预计第一季度归母净利润5.9亿元,同比增长43.73%
智通财经 · 03-03 17:40
艾力斯(688578.SH)发预增,预计第一季度归母净利润5.9亿元,同比增长43.73%
每周股票复盘:艾力斯(688578)2025年净利增52.55%
证券之星 · 03-01
每周股票复盘:艾力斯(688578)2025年净利增52.55%
艾力斯(688578)披露2025年度业绩快报,2月26日股价下跌1.74%
证券之星 · 02-26
艾力斯(688578)披露2025年度业绩快报,2月26日股价下跌1.74%
艾力斯(688578.SH)2025年度归母净利润21.81亿元,同比增长52.55%
智通财经网 · 02-26
艾力斯(688578.SH)2025年度归母净利润21.81亿元,同比增长52.55%
艾力斯(688578)披露2025年年度业绩预增公告,1月28日股价上涨1.25%
证券之星 · 01-28
艾力斯(688578)披露2025年年度业绩预增公告,1月28日股价上涨1.25%
艾力斯(688578.SH)发预增,预计2025年度归母净利润21.5亿元,同比增加50.37%
智通财经 · 01-28
艾力斯(688578.SH)发预增,预计2025年度归母净利润21.5亿元,同比增加50.37%
艾力斯:目前已有两款产品进入CMC开发阶段
证券日报 · 01-21
艾力斯:目前已有两款产品进入CMC开发阶段
艾力斯:公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可
证券日报 · 01-21
艾力斯:公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可
艾力斯(688578.SH):甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示
智通财经 · 2025-12-25
艾力斯(688578.SH):甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示
艾力斯(688578)披露使用部分暂时闲置募集资金进行现金管理,12月15日股价上涨2.0%
证券之星 · 2025-12-15
艾力斯(688578)披露使用部分暂时闲置募集资金进行现金管理,12月15日股价上涨2.0%
12月12日艾力斯现1笔大宗交易 机构净买入943.81万元
证券之星 · 2025-12-12
12月12日艾力斯现1笔大宗交易 机构净买入943.81万元
艾力斯(688578)披露公司创新药品纳入新版国家医保目录,12月08日股价上涨1.17%
证券之星 · 2025-12-08
艾力斯(688578)披露公司创新药品纳入新版国家医保目录,12月08日股价上涨1.17%
艾力斯(688578.SH):创新药伏美替尼、戈来雷塞纳入新版国家医保目录
智通财经 · 2025-12-07
艾力斯(688578.SH):创新药伏美替尼、戈来雷塞纳入新版国家医保目录
艾力斯:公司已具备2亿片甲磺酸伏美替尼片固体制剂生产能力
每日经济新闻 · 2025-11-28
艾力斯:公司已具备2亿片甲磺酸伏美替尼片固体制剂生产能力
艾力斯:董事会完成换届选举 杜锦豪为董事长兼总经理
财中社 · 2025-11-27
艾力斯:董事会完成换届选举 杜锦豪为董事长兼总经理
每周股票复盘:艾力斯(688578)拟取消监事会,调整董事会结构
证券之星 · 2025-11-23
每周股票复盘:艾力斯(688578)拟取消监事会,调整董事会结构
艾力斯(688578)披露拟取消监事会并调整董事会架构,11月21日股价下跌0.12%
证券之星 · 2025-11-21
艾力斯(688578)披露拟取消监事会并调整董事会架构,11月21日股价下跌0.12%
每周股票复盘:艾力斯(688578)将参加2025年上海辖区三季报业绩说明会
证券之星 · 2025-11-09
每周股票复盘:艾力斯(688578)将参加2025年上海辖区三季报业绩说明会
加载更多
公司概况
公司名称:
上海艾力斯医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-02
主营业务:
上海艾力斯医药科技股份有限公司的主营业务是肿瘤治疗领域的创新药研发、生产及销售。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。公司于2023年获评“中国医药创新企业100强”,并荣获上海市创新型企业总部认定授牌。2024年3月,公司荣登“2023中国创新药上市公司价值引领TOP15”榜单。2024年4月,公司荣获浦东新区“2023年度科技创新突出贡献奖”。2024年10月,公司获得上海市第32批市级企业技术中心认定。2025年4月,公司获得“2024年度浦东新区先进制造业突出贡献奖”。2025年6月,公司获得第二十五届中国专利金奖。
发行价格:
22.73
{"stockData":{"symbol":"688578","market":"SH","secType":"STK","nameCN":"艾力斯","latestPrice":96.44,"timestamp":1772694001000,"preClose":100.05,"halted":0,"volume":8103940,"delay":0,"changeRate":-0.0361,"floatShares":450000000,"shares":450000000,"eps":4.406,"marketStatus":"已收盘","change":-3.61,"latestTime":"03-05 15:00:01","open":98.42,"high":100,"low":95.72,"amount":789000000,"amplitude":0.0428,"askPrice":96.45,"askSize":5,"bidPrice":96.44,"bidSize":22,"shortable":0,"etf":0,"ttmEps":4.406,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":100.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":110.06,"lowLimit":90.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":6.68,"roa":"--","peRate":21.888334,"roe":"27.92%","epsLYR":3.18,"committee":0.202864,"marketValue":43398000000,"turnoverRate":0.018,"status":1,"afterMarket":{"amount":0,"volume":0,"close":96.44,"buyVolume":0,"sellVolume":0,"time":1772696037558,"indexStatus":"已收盘 03-05 15:30:00","preClose":100.05},"floatMarketCap":43398000000},"requestUrl":"/m/hq/s/688578","defaultTab":"news","newsList":[{"id":"2616899580","title":"3月4日艾力斯涨11.17%,银华中证创新药产业ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616899580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616899580?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:22","pubTimestamp":1772612539,"startTime":"0","endTime":"0","summary":"证券之星消息,3月4日艾力斯涨11.17%,收盘报100.05元,换手率3.12%,成交量14.04万手,成交额13.82亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共50家,其中持有数量最多的公募基金为银华基金的银华中证创新药产业ETF。银华中证创新药产业ETF目前规模为124.21亿元,最新净值0.7781,较上一交易日下跌2.79%,近一年上涨8.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400027757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688578","BK1574","159992","BK0239","06978"],"gpt_icon":0},{"id":"2616346345","title":"艾力斯:预计2026年1-3月营业收入15.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616346345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616346345?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:00","pubTimestamp":1772532025,"startTime":"0","endTime":"0","summary":"证券之星消息,艾力斯发布业绩预告,预计2026年1-3月营业收入15.5亿元。艾力斯2025年三季报显示,前三季度公司主营收入37.33亿元,同比上升47.35%;归母净利润16.16亿元,同比上升52.01%;扣非净利润14.52亿元,同比上升43.62%;其中2025年第三季度,公司单季度主营收入13.59亿元,同比上升42.03%;单季度归母净利润5.65亿元,同比上升38.77%;单季度扣非净利润5.46亿元,同比上升50.2%;负债率10.48%,投资收益1305.31万元,财务费用-3402.25万元,毛利率96.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300032624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578"],"gpt_icon":0},{"id":"2616438863","title":"艾力斯(688578.SH)发预增,预计第一季度归母净利润5.9亿元,同比增长43.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616438863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616438863?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:40","pubTimestamp":1772530817,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯(688578.SH)发布公告,公司预计2026年第一季度实现归属于母公司所有者的净利润为5.9亿元,同比增长43.73%。受益于国家医保政策的支持与覆盖,公司商业化产品销售收入及推广服务收入持续增长,推动公司经营业绩继续攀升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾力斯(688578.SH)发预增,预计第一季度归母净利润5.9亿元,同比增长43.73%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"gpt_icon":0},{"id":"2616438628","title":"每周股票复盘:艾力斯(688578)2025年净利增52.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616438628","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616438628?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:44","pubTimestamp":1772300654,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,艾力斯报收于92.71元,较上周的95.68元下跌3.1%。本周,艾力斯2月24日盘中最高价报96.6元。本周关注点来自业绩披露要点:艾力斯2025年归属净利润同比增长52.55%,达21.813亿元。公司公告汇总上海艾力斯医药科技股份有限公司发布2025年度业绩快报,营业总收入为517,170.56万元,同比增长45.36%;归属于母公司所有者的净利润为218,129.29万元,同比增长52.55%。主要原因为核心产品甲磺酸伏美替尼片销售放量,推动收入和利润大幅增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2614028513","title":"艾力斯(688578)披露2025年度业绩快报,2月26日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028513","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614028513?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:22","pubTimestamp":1772115738,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘,艾力斯报收于92.73元,较前一交易日下跌1.74%,最新总市值为417.28亿元。该股当日开盘94.01元,最高94.49元,最低92.3元,成交额达3.51亿元,换手率为0.84%。近日,上海艾力斯医药科技股份有限公司发布2025年度业绩快报,营业总收入为517,170.56万元,同比增长45.36%;归属于母公司所有者的净利润为218,129.29万元,同比增长52.55%。该数据为初步核算,未经审计,最终以2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2614772018","title":"艾力斯(688578.SH)2025年度归母净利润21.81亿元,同比增长52.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772018","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614772018?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:24","pubTimestamp":1772094280,"startTime":"0","endTime":"0","summary":"艾力斯(688578.SH)披露2025年度业绩快报,2025年度实现营业总收入51.72亿元,同比增长45.36%;归属于母公司所有者的净利润21.81亿元,同比增长52.55%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688578"],"gpt_icon":0},{"id":"2606717194","title":"艾力斯(688578)披露2025年年度业绩预增公告,1月28日股价上涨1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717194","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717194?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:30","pubTimestamp":1769610636,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘,艾力斯报收于101.3元,较前一交易日上涨1.25%,最新总市值为455.85亿元。近日,上海艾力斯医药科技股份有限公司发布2025年年度业绩预增公告。公告显示,公司预计2025年度实现营业收入520,000.00万元,同比增长46.15%;归属于母公司所有者的净利润为215,000.00万元,同比增长50.37%;扣除非经常性损益后的净利润为200,000.00万元,同比增长46.95%。上述数据未经注册会计师审计,具体以2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2606796565","title":"艾力斯(688578.SH)发预增,预计2025年度归母净利润21.5亿元,同比增加50.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606796565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606796565?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:36","pubTimestamp":1769589377,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯(688578.SH)发布公告,公司预计2025年度实现归属于母公司所有者的净利润为21.5亿元,同比增加50.37%。公司商业化产品聚焦肺癌精准治疗领域,通过差异化的临床治疗优势和专业化的学术推广策略受到业内专家的高度认可。受益于国家医保政策“让新药、好药更加触手可及”的支持与覆盖,公司核心产品销售收入持续增长。此外,公司充分优化资源配置、积极发挥商业化产品间的协同效应,形成多层次的发展动力,推动公司经营业绩持续攀升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578"],"gpt_icon":0},{"id":"2605146100","title":"艾力斯:目前已有两款产品进入CMC开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2605146100","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605146100?lang=zh_cn&edition=full","pubTime":"2026-01-21 21:12","pubTimestamp":1769001120,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月21日,艾力斯在互动平台回答投资者提问时表示,公司长期以来致力于小分子创新药物研发,在巩固提升小分子创新药物研发的基础上,近年来公司组建了大分子新药发现团队,搭建了大分子新药研发平台,进一步提升公司研发团队的创新活力。公司大分子团队多个早研项目均在高效有序推进过程中,目前已有两款产品进入CMC开发阶段,希望可以尽快申报IND。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288113.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443622.USD","LU0149725797.USD","LU2237443465.HKD","LU2237443382.USD","LU1363072403.SGD","LU2237443895.HKD","LU0170899867.USD","IE00B1BXHZ80.USD","LU2746668461.USD","BK0239","LU0267386448.USD","LU2237443549.SGD","IE00BFXG1179.USD","688578","LU2237443978.SGD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU2746668974.SGD","BK4006","LU0971096721.USD","CMC","IE00BHPRN162.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2605127100","title":"艾力斯:公司自主研发的KRAS G12D选择性抑制剂已于2024年3月获得临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2605127100","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605127100?lang=zh_cn&edition=full","pubTime":"2026-01-21 21:12","pubTimestamp":1769001120,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月21日,艾力斯在互动平台回答投资者提问时表示,公司自主研发的KRASG12D选择性抑制剂已于2024年3月获得临床试验默示许可;公司从和誉医药引进的新一代EGFR口服小分子抑制剂已于2024年9月获得临床试验默示许可。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288254.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-21/doc-inhiaqzp5288254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2594234512","title":"艾力斯(688578.SH):甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示","url":"https://stock-news.laohu8.com/highlight/detail?id=2594234512","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594234512?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:23","pubTimestamp":1766665420,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯 发布公告,公司核心产品甲磺酸伏美替尼片近日被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单,拟定适应症为具有表皮生长因子受体PACC突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗,公示期为2025年12月25日—2026年1月4日。目前,伏美替尼一线及二线治疗适应症均已纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾力斯(688578.SH):甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2591642339","title":"艾力斯(688578)披露使用部分暂时闲置募集资金进行现金管理,12月15日股价上涨2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642339","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642339?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:18","pubTimestamp":1765808297,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘,艾力斯报收于101.12元,较前一交易日上涨2.0%,最新总市值为455.04亿元。该股当日开盘99.05元,最高102.17元,最低98.77元,成交额达3.65亿元,换手率为0.8%。近日,上海艾力斯医药科技股份有限公司发布关于使用部分暂时闲置募集资金进行现金管理的公告。使用期限自董事会审议通过之日起12个月内有效,可循环滚动使用。该事项无需提交股东大会审批,保荐人中信证券无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500035507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2590577554","title":"12月12日艾力斯现1笔大宗交易 机构净买入943.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577554","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577554?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:58","pubTimestamp":1765533527,"startTime":"0","endTime":"0","summary":"证券之星消息,12月12日艾力斯发生大宗交易,交易数据如下:大宗交易成交价格99.14元,成交9.52万股,成交金额943.81万元,买方营业部为机构专用,卖方营业部为瑞银证券有限责任公司上海花园石桥路证券营业部。近三个月该股共发生12笔大宗交易,合计成交9233.0手,折价成交11笔。截至2025年12月12日收盘,艾力斯报收于99.14元,上涨1.03%,换手率1.61%,成交量7.24万手,成交额7.15亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2589933989","title":"艾力斯(688578)披露公司创新药品纳入新版国家医保目录,12月08日股价上涨1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589933989","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589933989?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:48","pubTimestamp":1765187309,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘,艾力斯报收于97.4元,较前一交易日上涨1.17%,最新总市值为438.3亿元。近日,上海艾力斯医药科技股份有限公司发布自愿披露公告,公司创新药甲磺酸伏美替尼片和枸橼酸戈来雷塞片均被纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。伏美替尼一线及二线治疗适应症经谈判继续纳入,戈来雷塞二线治疗适应症首次纳入。协议有效期为2026年1月1日至2027年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688578"],"gpt_icon":0},{"id":"2589879337","title":"艾力斯(688578.SH):创新药伏美替尼、戈来雷塞纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879337","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879337?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:02","pubTimestamp":1765094576,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾力斯(688578.SH)发布公告,公司创新药品甲磺酸伏美替尼片(商品名“艾弗沙®️”,以下简称“伏美替尼”)和枸橼酸戈来雷塞片(商品名“艾瑞凯®️”,以下简称“戈来雷塞”)均被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称“国家医保目录”)。其中,伏美替尼一线及二线治疗适应症经医保谈判后继续纳入国家医保目录;戈来雷塞二线治疗适应症通过医保谈判方式首次被纳入国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688578","06978","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2586781957","title":"艾力斯:公司已具备2亿片甲磺酸伏美替尼片固体制剂生产能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2586781957","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586781957?lang=zh_cn&edition=full","pubTime":"2025-11-28 19:39","pubTimestamp":1764329940,"startTime":"0","endTime":"0","summary":"艾力斯11月28日在投资者互动平台表示,公司全资子公司江苏艾力斯生物医药有限公司新增年产1.5亿片甲磺酸伏美替尼片固体制剂生产线已于2025年7月取得江苏省药品监督管理局GMP符合性证明文件,已满足药品监督管理部门的许可生产条件并获批投产,包括原有年产5000万片甲磺酸伏美替尼片固体制剂生产线,公司已具备2亿片甲磺酸伏美替尼片固体制剂生产能力,进一步保障了产品供应能力,为持续增长的市场需求提供有力支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-28/doc-infyyhva7250020.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-28/doc-infyyhva7250020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2586228485","title":"艾力斯:董事会完成换届选举 杜锦豪为董事长兼总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228485","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586228485?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:29","pubTimestamp":1764246540,"startTime":"0","endTime":"0","summary":"艾力斯发布公告,公司于2025年11月27日召开第三届董事会第一次会议,选举产生了第三届董事会的董事长、副董事长及各专门委员会委员,并聘任了高级管理人员及证券事务代表。 董事会成员包括非独立董事杜锦豪(董事长)、祁菊、胡捷、徐锋、徐聪,独立董事朱茶芬、李翰杰、李成璋,以及职工代表董事储胜明,任期自股东大会审议通过之日起三年。 2025年前三季度,艾力斯实现收入37.33亿元,归母净利润16.16亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-27/doc-infywcvy9118131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2585103359","title":"每周股票复盘:艾力斯(688578)拟取消监事会,调整董事会结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103359?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:09","pubTimestamp":1763834952,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,艾力斯报收于95.49元,较上周的102.12元下跌6.49%。本周,艾力斯11月17日盘中最高价报101.88元。艾力斯当前最新总市值429.7亿元,在化学制药板块市值排名11/151,在两市A股市值排名396/5167。本周关注点公司公告汇总:艾力斯拟取消监事会,其职能由董事会审计委员会承接。公司公告汇总:董事会成员将调整为8-11名,并增设1名职工代表董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2585149666","title":"艾力斯(688578)披露拟取消监事会并调整董事会架构,11月21日股价下跌0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149666","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585149666?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:25","pubTimestamp":1763735115,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,艾力斯报收于95.49元,较前一交易日下跌0.12%,最新总市值为429.7亿元。该股当日开盘95.7元,最高97.36元,最低94.84元,成交额达3.54亿元,换手率为0.82%。近日,上海艾力斯医药科技股份有限公司发布2025年第一次临时股东大会会议资料,宣布拟对公司治理结构进行调整。公告显示,公司拟取消监事会,其职能由董事会审计委员会承接;董事会成员人数将调整为8至11名,并增设1名职工代表董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0},{"id":"2582861843","title":"每周股票复盘:艾力斯(688578)将参加2025年上海辖区三季报业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861843","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861843?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:30","pubTimestamp":1762630238,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,艾力斯报收于101.0元,较上周的107.55元下跌6.09%。本周关注点公司公告汇总:艾力斯将参加2025年上海辖区上市公司三季报集体业绩说明会,投资者可提前提交问题。公司公告汇总上海艾力斯医药科技股份有限公司将于2025年11月13日(星期四)下午15:00-16:30参加“2025年上海辖区上市公司三季报集体业绩说明会”,通过上证路演中心以网络文字互动方式召开。会议将就公司2025年第三季度及前三季度的经营成果、财务状况等与投资者进行交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772748421876,"stockEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":-0.0042},{"period":"3month","weight":0.0018},{"period":"6month","weight":-0.1746},{"period":"1year","weight":0.2225},{"period":"ytd","weight":-0.074}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海艾力斯医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19107人(较上一季度增加46.82%)","perCapita":"23551股","listingDate":"2020-12-02","address":"上海市浦东新区周浦镇凌霄花路268号","registeredCapital":"45000万元","survey":" 上海艾力斯医药科技股份有限公司的主营业务是肿瘤治疗领域的创新药研发、生产及销售。公司的主要产品是甲磺酸伏美替尼片、枸橼酸戈来雷塞片、普拉替尼胶囊。公司于2023年获评“中国医药创新企业100强”,并荣获上海市创新型企业总部认定授牌。2024年3月,公司荣登“2023中国创新药上市公司价值引领TOP15”榜单。2024年4月,公司荣获浦东新区“2023年度科技创新突出贡献奖”。2024年10月,公司获得上海市第32批市级企业技术中心认定。2025年4月,公司获得“2024年度浦东新区先进制造业突出贡献奖”。2025年6月,公司获得第二十五届中国专利金奖。","listedPrice":22.73},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾力斯,688578,艾力斯股票,艾力斯股票老虎,艾力斯股票老虎国际,艾力斯行情,艾力斯股票行情,艾力斯股价,艾力斯股市,艾力斯股票价格,艾力斯股票交易,艾力斯股票购买,艾力斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾力斯(688578)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾力斯(688578)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}